FDA Approves GSK's Oral Antibiotic For Urinary Tract Infections For Females Aged 12 Years And Older

The US Food and Drug Administration (FDA) approved GSK plc’s (NYSE:GSK) Blujepa (gepotidacin) for the treatment of female adults (≥40 kg) and pediatric patients (≥12 years, ≥40 kg) with uncomplicated urinary tract infections (uUTIs).

In a press release on Tuesday, the company said the U.S. commercial launch is planned in 2H 2025.

UTIs are the most common infection in women, impacting up to 16 million women in the US ...